UY30573A1 - N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 - Google Patents
N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2Info
- Publication number
- UY30573A1 UY30573A1 UY30573A UY30573A UY30573A1 UY 30573 A1 UY30573 A1 UY 30573A1 UY 30573 A UY30573 A UY 30573A UY 30573 A UY30573 A UY 30573A UY 30573 A1 UY30573 A1 UY 30573A1
- Authority
- UY
- Uruguay
- Prior art keywords
- het
- piperidin
- hetaril
- arilamids
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invencion se refiere a (het)aril-3-[ het)aril-piperidin-4-il]-amida, a procedimientos para su preparacion, así como a su uso para la preparacion de agentes farmacéuticos para el tratamiento de enfermedades e indicaciones que están relacionadas con el receptor EP2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06090160A EP1903038A1 (de) | 2006-09-07 | 2006-09-07 | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30573A1 true UY30573A1 (es) | 2008-05-02 |
Family
ID=37660246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30573A UY30573A1 (es) | 2006-09-07 | 2007-09-05 | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080125463A1 (es) |
EP (2) | EP1903038A1 (es) |
JP (1) | JP2010502665A (es) |
AR (1) | AR062696A1 (es) |
CA (1) | CA2662281A1 (es) |
CL (1) | CL2007002595A1 (es) |
PE (1) | PE20080827A1 (es) |
TW (1) | TW200819131A (es) |
UY (1) | UY30573A1 (es) |
WO (1) | WO2008028691A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
CA2788450A1 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted naphthalenyl-pyrimidine compounds |
BR112012022868A2 (pt) * | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morfolinilquinazolinas |
AR083199A1 (es) | 2010-09-29 | 2013-02-06 | Intervet Internationale B V | Compuestos de n-heteroarilo con unidad de puente ciclico |
AU2011310592B2 (en) | 2010-09-29 | 2015-01-22 | Intervet International B.V. | N-heteroaryl compounds |
JP5935154B2 (ja) * | 2011-03-14 | 2016-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gpr119モジュレーターとしてのn−シクロプロピル−n−ピペリジニルベンズアミド |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
US9260441B2 (en) | 2012-03-28 | 2016-02-16 | Intervet Inc. | Heteroaryl compounds with cyclic bridging unit |
EP2831042B1 (en) | 2012-03-28 | 2019-07-31 | Intervet International B.V. | Heteroaryl compounds with a-cyclic bridging unit |
RU2638540C1 (ru) | 2012-04-24 | 2017-12-14 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
HRP20211855T1 (hr) | 2013-03-12 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Inhibitori dnk-pk |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
MA41168A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
KR20180094939A (ko) * | 2015-12-17 | 2018-08-24 | 메르크 파텐트 게엠베하 | 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도 |
SG11201900947RA (en) | 2016-08-08 | 2019-02-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
JPH11171774A (ja) * | 1997-12-05 | 1999-06-29 | Kyowa Hakko Kogyo Co Ltd | 血球増多剤 |
WO1999053924A1 (fr) * | 1998-04-17 | 1999-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent analgesique |
WO2002009717A1 (fr) * | 2000-07-31 | 2002-02-07 | Ono Pharmaceutical Co., Ltd. | Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif |
DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
-
2006
- 2006-09-07 EP EP06090160A patent/EP1903038A1/de not_active Withdrawn
-
2007
- 2007-09-04 TW TW096132944A patent/TW200819131A/zh unknown
- 2007-09-05 UY UY30573A patent/UY30573A1/es not_active Application Discontinuation
- 2007-09-06 US US11/896,922 patent/US20080125463A1/en not_active Abandoned
- 2007-09-06 JP JP2009527070A patent/JP2010502665A/ja active Pending
- 2007-09-06 EP EP07802347A patent/EP2066654A1/en not_active Withdrawn
- 2007-09-06 CL CL200702595A patent/CL2007002595A1/es unknown
- 2007-09-06 WO PCT/EP2007/008083 patent/WO2008028691A1/en active Application Filing
- 2007-09-06 PE PE2007001191A patent/PE20080827A1/es not_active Application Discontinuation
- 2007-09-06 CA CA002662281A patent/CA2662281A1/en not_active Abandoned
- 2007-09-07 AR ARP070103953A patent/AR062696A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20080827A1 (es) | 2008-08-23 |
EP2066654A1 (en) | 2009-06-10 |
CL2007002595A1 (es) | 2008-04-18 |
AR062696A1 (es) | 2008-11-26 |
EP1903038A1 (de) | 2008-03-26 |
CA2662281A1 (en) | 2008-03-13 |
WO2008028691A1 (en) | 2008-03-13 |
TW200819131A (en) | 2008-05-01 |
JP2010502665A (ja) | 2010-01-28 |
US20080125463A1 (en) | 2008-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
PE20151065A1 (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
EA200800835A1 (ru) | Циклопропиламины в качестве модуляторов рецептора гистамина н | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
EA201370066A1 (ru) | Модуляторы эстрогеновых рецепторов и их применение | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
CL2007002199A1 (es) | Compuestos derivados de sulfonil amida, moduladores del receptor cb2; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias y autoinmune. | |
BRPI0917017B8 (pt) | inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos | |
NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
BRPI0614397A2 (pt) | compostos de pirimidina como moduladores de receptor de serotonina | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
SV2011003855A (es) | Heteroarilos sustituidos | |
EA200970067A1 (ru) | Агонисты ep2 | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
ATE517106T1 (de) | Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren | |
UY35073A (es) | Derivados de pirrolidinona como moduladores de GPR119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados. | |
BRPI1013259B8 (pt) | moduladores lxr | |
CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170726 |